Open AccessHigh doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study
Author(s) -
Barrios V.,
Escobar C.,
De La Figuera M.,
Honorato J.,
Llisterri J. L.,
Segura J.,
Calderón A.
Publication year - 2008
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/j.1742-1241.2008.01736.x
Subject(s) - medicine , lercanidipine , metabolic syndrome , drug tolerance , pharmacology , anesthesia , blood pressure , obesity
Summary Aims/Introduction: The TOlerabilidad de LERcanidipino 20 mg frente a Amlodipino y N ifedipino en C ondicion E s normales de uso study was aimed to compare the tolerability of high doses of lercanidipine with amlodipine and nifedipine gastro‐intestinal therapeutic system (GITS) in the treatment of hypertension in daily clinical practice. Patients/methods: Essential hypertensives ≥ 18 years, treated during at least 1 month with lercanidipine 20 mg, amlodipine 10 mg or nifedipine GITS 60 mg, after a previous treatment course of at least 1 month with half the dose of the corresponding drugs were included. We present the data of the subgroup of patients with metabolic syndrome (MetS). Results: Three hundred and thirty‐seven of the 650 study population fulfilled criteria of MetS, 233 (69.1%) on lercanidipine and 104 (30.9%) on amlodipine/nifedipine GITS. Overall, a significantly lower proportion of lercanidipine‐treated patients showed adverse reactions (ARs) when compared with patients receiving other‐dihydropyridines (DHPs) (60.1% vs. 73.1%, p = 0.003). Similarly, the most common vasodilation‐related ARs (oedema, swelling, flushing and headache) were significantly less frequent in lercanidipine group (all p < 0.01). Conclusion: In conclusion, lercanidipine appears to exhibit a better tolerability profile and less vasodilation‐related ARs compared with other DHPs in hypertensive patients with MetS.